Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)
Status:
Withdrawn
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
For MDS patients who have not responded to or have progressed after an initial response to
DNA methyltransferase inhibitors (DNMTI) and are not stem cell transplant candidates,
therapeutic options are limited. Participation in clinical trials such as this one may be
considered. The specific objectives of this trial are to find out which dose of ON 01910.Na
can be safety given to MDS patients and then find out if this dose of drug has any beneficial
effects on the patients' disease. ON 01910.Na is a new, experimental drug; the reason for
doing this trial is based on the anti-cancer activity of ON 01910.Na that has been observed
in laboratory experiments and in early clinical trials.